News | January 06, 2026
Dabur sees early demand recovery, rural sales lead growth in Q3 FY26
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Subscribe To Our Newsletter & Stay Updated
